Upstream Bio (UPB) Income towards Parent Company (2023 - 2026)
Upstream Bio (UPB) posted quarterly Income towards Parent Company of -$61.8 million for Q1 2026, down 77.23% year-over-year from -$271.3 million in Q1 2025, and up 69.83% quarter-over-quarter from -$204.8 million in Q4 2025.
Upstream Bio (UPB) Income towards Parent Company (2023 - 2026) Analysis & Trends
Upstream Bio's Income towards Parent Company history runs 4 years deep, the most recent figure standing at -$61.8 million for Q1 2026.
- In Q1 2026, Income towards Parent Company fell 77.23% year-over-year to -$61.8 million; the TTM figure through Mar 2026 stood at -$484.0 million (down 146.9% YoY), while the FY2025 annual figure was -$305.7 million, down 123.29% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$61.8 million, up from -$204.8 million in the prior quarter.
- The five-year high for Income towards Parent Company was -$7.9 million in Q3 2023, with the low at -$204.8 million in Q4 2025.
- The 4-year median for Income towards Parent Company is -$52.5 million (2023), against an average of -$68.7 million.
- Peak annual rise in Income towards Parent Company reached 76.19% in 2024, while the deepest fall reached 549.96% in 2024.
- Upstream Bio's Income towards Parent Company stood at -$52.5 million in 2023, then slumped by 76.19% to -$92.5 million in 2024, then plunged by 121.38% to -$204.8 million in 2025, then jumped by 69.83% to -$61.8 million in 2026.
- Business Quant data shows UPB's Income towards Parent Company at -$61.8 million in Q1 2026, -$204.8 million in Q4 2025, and -$133.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Upstream Bio | 387.23 Mn | 387.23 Mn | -3.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -48.87 Mn |
| Mar 31, 2026 | -61.79 Mn |
| Dec 31, 2025 | -204.79 Mn |
| Sep 30, 2025 | -133.27 Mn |
| Jun 30, 2025 | -84.15 Mn |
| Mar 31, 2025 | -34.86 Mn |
| Dec 31, 2024 | -92.51 Mn |
| Sep 30, 2024 | -51.08 Mn |
| Jun 30, 2024 | -17.57 Mn |
| Mar 31, 2024 | -15.06 Mn |
| Dec 31, 2023 | -52.51 Mn |
| Sep 30, 2023 | -7.86 Mn |